Upregulation of maspin expression in human cervical carcinoma cells by transforming growth factor β1 through the convergence of Smad and non‑Smad signaling pathways

Wongnoppavich,Ariyaphong; Dukaew,Nahathai; Choonate,Sirinthip; Chairatvit,Kongthawat

doi:10.3892/ol.2017.5939

Upregulation of maspin expression in human cervical carcinoma cells by transforming growth factor β1 through the convergence of Smad and non‑Smad signaling pathways

Authors:
- Ariyaphong Wongnoppavich
- Nahathai Dukaew
- Sirinthip Choonate
- Kongthawat Chairatvit
View Affiliations

Affiliations: Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand, Department of Oral Biology, Faculty of Dentistry, Mahidol University, Bangkok 10400, Thailand
Published online on: March 28, 2017 https://doi.org/10.3892/ol.2017.5939
Pages: 3646-3652
Copyright: © Wongnoppavich et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mammary serine protease inhibitor (maspin), encoded by the serpin family B member 5 gene, serves as a tumor suppressor through the inhibition of cancer cell invasion and metastasis. Paradoxically, maspin levels are upregulated in a number of types of malignant cells. Therefore, the regulation of maspin expression may depend on the genetic or epigenetic background and the specific microenvironment of carcinoma cells. In the present study, it was demonstrated that transforming growth factor β1 (TGF‑β1) induced maspin expression at the transcript and protein levels in the human cervical carcinoma HeLa and human oral squamous carcinoma HSC4 cell lines. The inhibition of the mothers against decapentaplegic homolog (Smad)‑dependent pathway by a Smad3‑specific inhibitor suppressed maspin induction by TGF‑β1 in HeLa cells. Inhibition of the non‑Smad pathway by pretreatment with the mitogen‑activated protein kinase kinase 1/2 (MEK1/2) inhibitor U0126, or the p38 mitogen‑activated protein kinase (p38 MAPK) inhibitor SB202190, attenuated the effect of TGF‑β1 on maspin upregulation, whereas pretreatment with pyrrolidine dithiocarbamate (a nuclear factor κB inhibitor), wortmannin (a phosphoinositide 3‑kinase inhibitor) or SP600125 (a c‑Jun N‑terminal kinase inhibitor) did not. Notably, none of these inhibitors eliminated the TGF‑β1‑induced phosphorylation of Smad2. In addition, mutations at p53‑binding sites in the maspin promoter suppressed TGF‑β1‑induced maspin expression, indicating the necessity of intact p53‑binding sites on the maspin promoter. In summary, the induction of maspin expression in HeLa cells requires the convergence of TGF‑β1‑induced Smad and non‑Smad signaling pathways, in which the latter acts via the intermediate signaling molecules MEK1/2 and p38 MAPK.

View Figures

View References

1	Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB, Gettins PG, Irving JA, Lomas DA, Luke CJ, Moyer RW, et al: The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem. 276:33293–33296. 2001. View Article : Google Scholar : PubMed/NCBI
2	Bodenstine TM, Seftor RE, Khalkhali-Ellis Z, Seftor EA, Pemberton PA and Hendrix MJ: Maspin: Molecular mechanisms and therapeutic implications. Cancer Metastasis Rev. 31:529–551. 2012. View Article : Google Scholar : PubMed/NCBI
3	Zou Z, Anisowicz A, Hendrix MJ, Thor A, Neveu M, Sheng S, Rafidi K, Seftor E and Sager R: Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science. 263:526–529. 1994. View Article : Google Scholar : PubMed/NCBI
4	Beltran A, Parikh S, Liu Y, Cuevas BD, Johnson GL, Futscher BW and Blancafort P: Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors. Oncogene. 26:2791–2798. 2007. View Article : Google Scholar : PubMed/NCBI
5	Maass N, Nagasaki K, Ziebart M, Mundhenke C and Jonat W: Expression and regulation of tumor suppressor gene maspin in breast cancer. Clin Breast Cancer. 3:281–287. 2002. View Article : Google Scholar : PubMed/NCBI
6	Zou Z, Zhang W, Young D, Gleave MG, Rennie P, Connell T, Connelly R, Moul J, Srivastava S and Sesterhenn I: Maspin expression profile in human prostate cancer (CaP) and in vitro induction of Maspin expression by androgen ablation. Clin Cancer Res. 8:1172–1177. 2002.PubMed/NCBI
7	Bauerschlag DO, Habermann M, Weimer J, Meinhold-Heerlein I, Hilpert F, Weigel M, Bauer M, Mundhenke C, Jonat W, Maass N and Schem C: Heterogeneous expression of serine protease inhibitor maspin in ovarian cancer. Anticancer Res. 30:2739–2744. 2010.PubMed/NCBI
8	Frey A, Soubani AO, Adam AK, Sheng S, Pass HI and Lonardo F: Nuclear, compared with combined nuclear and cytoplasmic expression of maspin, is linked in lung adenocarcinoma to reduced VEGF-A levels and in Stage I, improved survival. Histopathology. 54:590–597. 2009. View Article : Google Scholar : PubMed/NCBI
9	Liu H, Shi J, Anandan V, Wang HL, Diehl D, Blansfield J, Gerhard G and Lin F: Reevaluation and identification of the best immunohistochemical panel (pVHL, Maspin, S100P, IMP-3) for ductal adenocarcinoma of the pancreas. Arch Pathol Lab Med. 136:601–609. 2012. View Article : Google Scholar : PubMed/NCBI
10	Cao D, Wilentz RE, Abbruzzese JL, Ho L and Maitra A: Aberrant expression of maspin in idiopathic inflammatory bowel disease is associated with disease activity and neoplastic transformation. Int J Gastrointest Cancer. 36:39–46. 2005. View Article : Google Scholar : PubMed/NCBI
11	Kim J, Jang KT, Kim KH, Park JW, Chang BJ, Lee KH, Lee JK, Heo JS, Choi SH, Choi DW, et al: Aberrant maspin expression is involved in early carcinogenesis of gallbladder cancer. Tumour Biol. 31:471–476. 2010. View Article : Google Scholar : PubMed/NCBI
12	Dinarello CA: The paradox of pro-inflammatory cytokines in cancer. Cancer Metastasis Rev. 25:307–313. 2006. View Article : Google Scholar : PubMed/NCBI
13	Gohji K, Nomi M, Hara I, Arakawa S and Kamidono S: Influence of cytokines and growth factors on matrix metalloproteinase-2 production and invasion of human renal cancer. Urol Res. 26:33–37. 1998. View Article : Google Scholar : PubMed/NCBI
14	Heldin CH and Moustakas A: Role of Smads in TGFb signaling. Cell Tissue Res. 347:21–36. 2012. View Article : Google Scholar : PubMed/NCBI
15	Mu Y, Gudey SK and Landström M: Non-Smad signaling pathways. Cell Tissue Res. 347:11–20. 2012. View Article : Google Scholar : PubMed/NCBI
16	Arteaga CL, Dugger TC and Hurd SD: The multifunctional role of transforming growth factor (TGF)-beta s on mammary epithelial cell biology. Breast Cancer Res Treat. 38:49–56. 1996. View Article : Google Scholar : PubMed/NCBI
17	Drabsch Y and ten Dijke P: TGF-b signaling in breast cancer cell invasion and bone metastasis. J Mammary Gland Biol Neoplasia. 16:97–108. 2011. View Article : Google Scholar : PubMed/NCBI
18	Wang SE, Narasanna A, Whitell CW, Wu FY, Friedman DB and Arteaga CL: Convergence of p53 and transforming growth factor beta (TGFbeta) signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells. J Biol Chem. 282:5661–5669. 2007. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Jung V, Pestka SB and Pestka S: Cloning of polymerase chain reaction-generated DNA containing terminal restriction endonuclease recognition sites. Methods Enzymol. 218:357–362. 1993. View Article : Google Scholar : PubMed/NCBI
21	Jinnin M, Ihn H and Tamaki K: Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression. Mol Pharmacol. 69:597–607. 2006. View Article : Google Scholar : PubMed/NCBI
22	Kumar S, Jiang MS, Adams JL and Lee JC: Pyridinylimidazole compound SB 203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase. Biochem Biophys Res Commun. 263:825–831. 1999. View Article : Google Scholar : PubMed/NCBI
23	Bailey CM, Khalkhali-Ellis Z, Seftor EA and Hendrix MJ: Biological functions of maspin. J Cell Physiol. 209:617–624. 2006. View Article : Google Scholar : PubMed/NCBI
24	Elston R and Inman GJ: Crosstalk between p53 and TGF-beta Signalling. J Signal Transduct. 2012:2940972012. View Article : Google Scholar : PubMed/NCBI
25	Cordenonsi M, Dupont S, Maretto S, Insinga A, Imbriano C and Piccolo S: Links between tumor suppressors: p53 is required for TGF-beta gene responses by cooperating with Smads. Cell. 113:301–314. 2003. View Article : Google Scholar : PubMed/NCBI
26	Poddar R and Paul S: Novel crosstalk between ERK MAPK and p38 MAPK leads to homocysteine-NMDA receptor-mediated neuronal cell death. J Neurochem. 124:558–570. 2013. View Article : Google Scholar : PubMed/NCBI
27	Huang C, Ma WY, Maxiner A, Sun Y and Dong Z: p38 kinase mediates UV-induced phosphorylation of p53 protein at serine 389. J Biol Chem. 274:12229–12235. 1999. View Article : Google Scholar : PubMed/NCBI
28	Cordenonsi M, Montagner M, Adorno M, Zacchigna L, Martello G, Mamidi A, Soligo S, Dupont S and Piccolo S: Integration of TGF-beta and Ras/MAPK signaling through p53 phosphorylation. Science. 315:840–843. 2007. View Article : Google Scholar : PubMed/NCBI
29	Yu L, Hebert MC and Zhang YE: TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J. 21:3749–3759. 2002. View Article : Google Scholar : PubMed/NCBI
30	Oshiro MM, Watts GS, Wozniak RJ, Junk DJ, Munoz-Rodriguez JL, Domann FE and Futscher BW: Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression. Oncogene. 22:3624–3634. 2003. View Article : Google Scholar : PubMed/NCBI
31	Horswill MA, Narayan M, Warejcka DJ, Cirillo LA and Twining SS: Epigenetic silencing of maspin expression occurs early in the conversion of keratocytes to fibroblasts. Exp Eye Res. 86:586–600. 2008. View Article : Google Scholar : PubMed/NCBI
32	Vo BT, Morton D Jr, Komaragiri S, Millena AC, Leath C and Khan SA: TGF-b effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway. Endocrinology. 154:1768–1779. 2013. View Article : Google Scholar : PubMed/NCBI
33	Ngamkitidechakul C, Warejcka DJ, Burke JM, O'Brien WJ and Twining SS: Sufficiency of the reactive site loop of maspin for induction of cell-matrix adhesion and inhibition of cell invasion. Conversion of ovalbumin to a maspin-like molecule. J Biol Chem. 278:31796–31806. 2003. View Article : Google Scholar : PubMed/NCBI
34	Yatabe Y, Mitsudomi T and Takahashi T: Maspin expression in normal lung and non-small-cell lung cancers: Cellular property-associated expression under the control of promoter DNA methylation. Oncogene. 23:4041–4049. 2004. View Article : Google Scholar : PubMed/NCBI
35	Friedrich MG, Toma MI, Petri S, Cheng JC, Hammerer P, Erbersdobler A and Huland H: Expression of Maspin in non-muscle invasive bladder carcinoma: Correlation with tumor angiogenesis and prognosis. Eur Urol. 45:737–743. 2004. View Article : Google Scholar : PubMed/NCBI
36	Rose SL, Fitzgerald MP, White NO, Hitchler MJ, Futscher BW, De Geest K and Domann FE: Epigenetic regulation of maspin expression in human ovarian carcinoma cells. Gynecol Oncol. 102:319–324. 2006. View Article : Google Scholar : PubMed/NCBI
37	Nosaka K, Horie Y, Shiomi T, Itamochi H, Oishi T, Shimada M, Sato S, Sakabe T, Harada T and Umekita Y: Cytoplasmic maspin expression correlates with poor prognosis of patients with adenocarcinoma of the uterine cervix. Yonago Acta Med. 58:151–156. 2015.PubMed/NCBI
38	Torres A, Torres K, Paszkowski T, Radej S, Staśkiewicz GJ, Ceccaroni M, Pesci A and Maciejewski R: Highly increased maspin expression corresponds with up-regulation of miR-21 in endometrial cancer: A preliminary report. Int J Gynecol Cancer. 21:8–14. 2011. View Article : Google Scholar : PubMed/NCBI
39	Goulet B, Kennette W, Ablack A, Postenka CO, Hague MN, Mymryk JS, Tuck AB, Giguère V, Chambers AF and Lewis JD: Nuclear localization of maspin is essential for its inhibition of tumor growth and metastasis. Lab Invest. 91:1181–1187. 2011. View Article : Google Scholar : PubMed/NCBI